Magdi Elsallab
YOU?
Author Swipe
View article: Charting the course for CAR T-cell manufacturing
Charting the course for CAR T-cell manufacturing Open
View article: ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies
ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies Open
View article: Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System
Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System Open
Second primary malignancies were reported in 536 of 12 394 (4.3%) adverse event reports following chimeric antigen receptor T-cell therapies in the Food and Drug Administration Adverse Event Reporting System. Myeloid and T-cell neoplasms w…
View article: CAR NK-92 cell–mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products
CAR NK-92 cell–mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products Open
Graft-versus-host disease (GVHD) is a major risk of the administration of allogeneic chimeric antigen receptor (CAR)-redirected T cells to patients who are HLA unmatched. Gene editing can be used to disrupt potentially alloreactive T-cell …
View article: Data from Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Data from Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy Open
As of April 2021, there are five commercially available chimeric antigen receptor (CAR) T cell therapies for hematologic malignancies. With the current transition of CAR T cell manufacturing from academia to industry, there is a shift towa…
View article: Data from Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Data from Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy Open
As of April 2021, there are five commercially available chimeric antigen receptor (CAR) T cell therapies for hematologic malignancies. With the current transition of CAR T cell manufacturing from academia to industry, there is a shift towa…
View article: Supplementary Data from Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Supplementary Data from Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy Open
Supplementary Data from Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
View article: Supplementary Data from Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Supplementary Data from Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy Open
Supplementary Data from Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
View article: Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis
Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis Open
Chimeric Antigen Receptor (CAR) T cell therapy is an effective treatment approach for patients with relapsed or refractory acute lymphoblastic leukemia (R/R B-ALL). However, identifying the factors that influence long-term response to this…
View article: Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy Open
As of April 2021, there are five commercially available chimeric antigen receptor (CAR) T cell therapies for hematologic malignancies. With the current transition of CAR T cell manufacturing from academia to industry, there is a shift towa…
View article: Detection of SARS‐CoV‐2‐specific memory B cells to delineate long‐term COVID‐19 immunity
Detection of SARS‐CoV‐2‐specific memory B cells to delineate long‐term COVID‐19 immunity Open
The COVID-19 pandemic has led to devastating health outcomes with the death toll exceeding two million cases as of February 2021. However, there is still limited data on long-term immunity against SARS-CoV-2. Long-term immunity can be anal…
View article: Detection of SARS-CoV-2 Specific Memory B cells to Delineate Long-Term COVID-19 Immunity
Detection of SARS-CoV-2 Specific Memory B cells to Delineate Long-Term COVID-19 Immunity Open
Background: The ongoing COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, represents a serious worldwide health concern. A deeper understanding of the immune response to SARS-CoV-2 will be required to refine vaccine developmen…
View article: Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals
Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals Open
View article: CAR T-cell product performance in haematological malignancies before and after marketing authorisation
CAR T-cell product performance in haematological malignancies before and after marketing authorisation Open
View article: Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions
Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions Open
The promise of stem cell (SC) therapies to restore functions of damaged tissues and organs brings enormous hope to patients, their families, loved ones, and caregivers. However, limits may exist for which indications SC therapies might be …